Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?

dc.contributorPontifícia Universidade Católica do Paraná (PUC-PR)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.creatorKotze, Paulo Gustavo
dc.creatorHossne, Rogério Saad [UNESP]
dc.date2016-04-01T18:42:42Z
dc.date2016-04-01T18:42:42Z
dc.date2013
dc.date.accessioned2023-09-12T09:09:01Z
dc.date.available2023-09-12T09:09:01Z
dc.identifierhttp://dx.doi.org/10.5217/ir.2013.11.4.256
dc.identifierIntestinal Research, v. 11, n. 4, p. 256-260, 2013.
dc.identifier1598-9100
dc.identifierhttp://hdl.handle.net/11449/136813
dc.identifier10.5217/ir.2013.11.4.256
dc.identifierISSN1598-9100-2013-11-04-256-260.pdf
dc.identifier9526345156590477
dc.identifier9526345156590477
dc.identifier9526345156590477
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8786057
dc.descriptionIn most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD.
dc.descriptionPontifícia Universidade Católica do Paraná (PUC-PR), Departamento de Cirurgia, Curitiba, PR, Brasil
dc.descriptionUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu (FMB), Departamento de Cirurgia e Ortopedia, Botucatu, SP, Brasil
dc.descriptionUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu (FMB), Departamento de Cirurgia e Ortopedia, Botucatu, SP, Brasil
dc.format256-260
dc.languageeng
dc.relationIntestinal Research
dc.relation1,074
dc.rightsAcesso aberto
dc.sourceCurrículo Lattes
dc.subjectTumor necrosis factor alpha
dc.subjectCrohn’s disease
dc.subjectRecurrence
dc.titleBiological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
dc.typeArtigo


Este ítem pertenece a la siguiente institución